NCT04259086

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI for Injection) for the Combined Treatment of Upper Facial Lines (Glabellar Lines, Dynamic Forehead Lines and Lateral Canthal Lines)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Revance Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL), and Lateral Canthal Lines(LCL)

Conditions

• Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)

Interventions

Type	Name	Description
DRUG	DaxibotulinumtoxinA for injection	Intramuscular injection

Timeline

• Start date: 2019-12-06
• Primary completion: 2020-11-02
• Completion: 2020-11-02
• First posted: 2020-02-06
• Last updated: 2023-06-27
• Results posted: 2023-06-27

Locations

8 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study